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Abstract: Malignant melanoma is one of the most aggressive human cancers. Invasion of cells is
the first step in metastasis, resulting in cell migration through tissue compartments.
We aimed to evaluate genomic alterations specifically associated with the invasive
characteristics of melanoma cells. Matrigel invasion assays were used to determine
the invasive properties of cell lines originated from primary melanomas. Array
comparative genomic hybridisation (aCGH) analyses were performed to define the
chromosome copy number alterations (CNAs).  Several recurrent CNAs were identified
by aCGH that affected melanoma-related genes. Invasive primary cell lines displayed
high frequencies of CNAs, including the loss of 7q and gain of 12q chromosomal
regions targeting PTPN12, ADAM22, FZD1, TFPI2, GNG11, COL1A2, SMURF1, VGF,
RELN and GLIPR1 genes.. Gain of the GDNF (5p13.1), GPAA1, PLEC and SHARPIN
(8q24.3) genes were significantly more frequent in invasive cell lines compared to the
non-invasive ones. Importantly, copy number gains of these genes were also found in
cell lines originated from metastases, suggesting their role in melanoma metastasis
formation.
The present study describes genomic differences between invasive and non-invasive
melanoma cell lines that may contribute to the aggressive phenotype of human
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
melanoma cells.
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Dear Professor Storkus, 
First we would like to thank you and the Reviewers for thoroughly reviewing our manuscript 
for thoroughly reviewing our manuscript (MR-D-15-00076).  
 
Please find below our responses for both Reviewers. 
We have answered all the comments and questions point by point.  
 
For the suggestion of the Reviewers we have performed additional experiments and analyses. 
It was unavoidable to write additional parts to the “Materials and Methods” as well as to the 
“Results” and the “Discussion” sections of the manuscript.  
 
We believe that the improved version of our manuscript will meet the high standards of 
Melanoma Research. 
 
We have uploaded 2 files of the manuscript, one is marked with the changes 
(Marked_MS_Koroknai_Revised) and the other one is without any labeling 
(MS_Koroknai_Revised). The new text (marked document) appears as underlined in red 
color text and the deleted parts appear as strikethrough text. 
 
 
 
 
Sincerely yours, 
 
 
Prof. Margit Balázs PhD, DSc 
University of Debrecen 
Faculty of Public Health,  
Department of Preventive Medicine 
Debrecen, Kassai str. 26/b Hungary 
email: balazs.margit@sph.unideb.hu 
Phone/FAX: (+36)-52-417-267  
Response to Reviewers
REVIEWER 1 
First we would like to thank the Reviewer for thoroughly reviewing our manuscript. For the 
suggestion of the Reviewer we performed new additional analyses as well as experiments. In 
our response we have labeled the Reviewer questions with bold italic. All additional 
descriptions added to the revised version have been marked as underlined subtitles and italic 
fonts   
 
Notes and questions arose by Reviewer 1: 
 
The authors performed array comparative genomic hybridization (aCGH) analyses to 
identify chromosome copy number alterations. They identified genomic differences 
between invasive and non-invasive melanoma cell lines. Overall the paper is well-
written. Although changes in the identified genes have been previously reported for 
their relevance in various invasive tumors, the authors now provide evidence that 
suggests relevance of alterations in expression levels of these gene products in 
invasive melanoma. Comments: 
 
 
1.) The authors should include information from publicly available databases showing copy 
number changes in the identified genes in melanoma patient samples. This will show the 
relevance of the identified genes in a larger population sample set. 
 
Following the suggestions of Reviewer 1, we included information from the publicly 
available melanoma dataset: The Cancer Genome Atlas (TCGA, Provisional). Using the 
visualization tools of the cBioPortal, (http://www.cbioportal.org) we downloaded the 
melanoma dataset containing GISTIC-CNA results of 366 melanoma samples. 
We have to note that aCGH data that are available in the data set were obtained mainly from 
metastatic melanoma tissue samples and regarding the invasive property of the primary 
tumors no data are listed in the TCGA database. On the other hand, the invasive capacity of 
primary melanoma cell lines that were used in our in vitro model systems cannot be precisely 
applied for melanoma tissues in the same context. As a systematic comparison is not possible 
between the public datasets and our results, we focused on genes (GDNF, GPAA1, PLEC and 
SHARPIN) that exhibited copy number alterations in both invasive and metastatic melanoma 
cell lines. These common alterations between the two distinct stages of tumor progression 
possibly reflect to genetic changes being responsible for the metastatic capacity of melanoma 
cells.  
Notably, the aforementioned genes exhibited copy number alterations exclusively in the 
metastatic tissues but not in the primary lesions. Interestingly, GPAA1, PLEC and SHARPIN 
genes were co-amplified in 26 metastatic melanomas. GDNF was found to be amplified to a 
lesser extent, in 14 metastatic tissues.  However, it must be noted again, that exact comparison 
is not possible with the public data. 
 
Additional section included into “Methods” (page 7, line 19): 
 
The Cancer Genome Atlas (TCGA) data analysis 
aCGH data of melanoma samples deposited into the Skin Cutaneous Melanoma dataset 
(TCGA, Provisional) were analyzed. The results shown are in whole based upon data 
generated by the TCGA Research Network (http://cancergenome.nih.gov). Dataset includes 
GISTIC-CNA data of 366 melanoma samples. Data mining was performed using cBioPortal 
(http://www.cbioportal.org/) [1, 2]. All searches were done according to the cBioPortal's 
instructions.  
 
 Page 9, line 20: new section inserted into the “Results”: 
Copy number alterations of candidate genes in melanoma tumor samples  
The Skin Cutaneous Melanoma dataset (TCGA, Provisional) gives the opportunity to 
determine the relevance of the alterations associated with invasive melanoma cell lines in 
native melanoma tissues. As most of the melanoma samples are metastatic and there is no 
available data regarding the invasive capacity of the primary tumors in the TCGA database, 
we focused on the genes (GDNF, GPAA1, PLEC, SHARPIN) which copy number alterations 
were detected not uniquely in invasive but also in metastasis-derived cell lines, assuming the 
role of these genes in both invasion and metastasis formation.. These genes were not altered 
by copy number changes in the primary lesion. Interestingly, GPAA1, PLEC and SHARPIN 
were co-amplified in 26 metastatic samples, whereas GDNF was found to be amplified only in 
14 metastatic tissues.  
Page 12, lines 15-21 were changed in the “Discussion” as follows: 
 
We found that the gain of GDNF (5p13.1), GPAA1, PLEC and SHARPIN (8q24.3) genes was 
detected in invasive and metastatic cell lines, indicating the possible roles of these genes in 
both invasion and metastasis formation. In addition, these genes showed copy number 
alterations in metastatic melanoma tissues of the TCGA (Provisional) melanoma dataset, 
supporting the relevance of these genes during the progression, metastasis formation of 
melanoma cells. 
 
2.) In the materials and methods, the authors mention “Melanoma cell lines were obtained 
from the American Type Culture Collection (Manassas, VA, USA) and the Coriell Institute 
for Medical Research (Camden, NJ, USA).” Include the information regarding which cell 
lines were obtained from which source. 
 
In agreement with the Reviewer we included the sources of the cell lines into the ”Materials 
and methods” section. 
 
Page 4, lines 10-14 were changed in the “Methods” section as follows:  
 
Melanoma cell lines (WM35, HT199, A2058, HT168, M24, M24 MET) were obtained from 
the American Type Culture Collection (Manassas, VA, USA) and the other cell lines 
(WM1789, WM793B, WM3211, WM1361, WM902B, WM39, WM278, WM983A, WM1366, 
WM3248, WM1617, WM983B) were from the Coriell Institute for Medical Research 
(Camden, NJ, USA).  
 
 
3.) In Figure 3, please provide information in the figure legend regarding which cell lines 
were analyzed in each of the categories – non-invasive, invasive and metastasis. 
 
In agreement with this comment the figure legend of Figure 3 has been completed with the list 
of the cell lines which were analyzed in the different categories.  
 
Page 15, line 13: corrected figure legend: 
 
Figure 3. Characterisation of invasive primary melanoma cell lines by aCGH (A) CN (copy 
number) changes uniquely observed in invasive primary cell lines (HT199, WM983A, 
WM1366, WM3211) in contrast with non-invasive primary- (WM35, WM1798, WM793B, 
WM1361, WM902B, WM39, WM278, WM3248) and metastatic-tumour derived cells (A2058, 
HT168, M24, M24 MET, WM1617, WM983B) targeting invasion associated genes. (B) CN 
changes detected in both invasive primary tumour-derived and metastatic-tumour derived cell 
lines targeting invasion related candidate genes. 
 
 
4.) The authors should provide information regarding the invasiveness of the metastatic 
cell lines utilized. Was the invasiveness similar in level to the primary invasive cell lines? 
 
In agreement with the Reviewer’s suggestion we performed additional analysis to provide 
data of the invasiveness of metastatic cell lines. Based on these experiments five of the six 
metastasis-derived cell lines (WM983B, A2058, HT168, M24 and M24 MET) were invasive 
at the similar level to the primary invasive cell lines.  
 
According to this suggestion we completed Table 1 with the results regarding the 
invasiveness of every cell line and added the means +/- SD of three independent invasion 
assays.   
 
 
Completed Table 1: 
 
Table 1 Characteristics of human melanoma cell lines 
Cell line Origina 
Growth 
Phaseb 
Histologic 
Typec 
BRAF 
mutation 
statusd 
NRAS 
mutation 
statuse 
Invaded 
cell/field 
(mean ± SD)f 
WM35 primary RGP SSM V600E wt 0.0 ± 0.0 
HT199 primary RGP NM V600E wt 15.0 ± 3.3 
WM1789 primary RGP/VGP SSM K601E wt 0.0 ± 0.0 
WM793B primary RGP/VGP SSM V600E wt 0.0 ± 0.0 
WM3211 primary RGP/VGP SSM wt wt 76.5 ± 29.5 
WM1361 primary VGP SSM wt Q61L 0.0 ± 0.0 
WM902B primary VGP SSM V600E wt 0.0 ± 0.0 
WM39 primary VGP NM V600E wt 0.0 ± 0.0 
WM278p1 primary VGP NM V600E wt 0.0 ± 0.0 
WM983Ap2 primary VGP n.d. V600E wt 4.7 ± 2.0 
WM1366 primary VGP n.d. wt Q61L 13.0 ± 1.4 
WM3248 primary VGP n.d. V600E wt 0.0 ± 0.0 
WM1617m1 metastasis - - V600E wt 0.0 ± 0.0 
WM983Bm2 metastasis - - V600E wt 3.3 ± 2.4 
A2058 metastasis - - V600E wt 30.0 ± 3.6 
HT168 metastasis - - V600E wt 26.7 ± 5.2 
M24 metastasis - - wt Q61R 27.0 ± 4.9 
M24 MET metastasis - - wt Q61R 74.0 ± 5.4 
atumor type of melanomas which the cell lines were derived from; bRGP: radial growth phase, 
VGP: vertical growth phase; cSSM: superficial spreading melanoma, NM: nodular melanoma, 
n.d.: no data; dV: valine, E: glutamic acid, K: lysine, wt: wild-type; eQ: glutamine, L: leucine, 
R: arginine; fdata are presented as the mean ± SD of three independent invasion assay 
experiments; pprimary tumor derived cell line with metastatic pair from the same patient; 
mmetastatic pair of primary derived cell line 
 
 
5.) Figure 3B-GDNF, the error bars between non-invasive, invasive and metastatic group 
are overlapping; are the data differences statistically significant? 
 
To compare copy number changes of invasive and non-invasive cell lines, Nexus Copy 
Number software was used. Nexus software performs two-tailed Fisher’s Exact test for 
multiple comparisons. The FDR adjustment was calculated to correct for multiple testing 
using the Nexus Copy Number 6.1 “Comparisons” feature.  We illustrated the copy number 
changes that displayed statistically significant differences between invasive and non-invasive 
cell lines.  
Accepting the criticism of the Reviewer, we corrected the inaccuracy of the column chart 
(Figure 3B) since the significant difference between invasive and non-invasive subgroups was 
based on the segmented values of the GNDF gene and not on the probe median data which 
was illustrated. In case of PLEC, SHARPIN and GPAA1 genes the correct segmented values 
were displayed in Figure 3B. Modified Figure 3 is the following: 
 
 
 
 
6.) The authors should perform some gain of function and loss of function experiments to 
validate some important genes they have identified in this study with the invasiveness 
features of the cell line panels (non-invasive, invasive and metastatic). If these types of 
studies are performed the impact of the work will be significantly enhanced.  
 In agreement with the Reviewer’s suggestion we performed additional analyses to validate 
candidate genes that were identified in our study. We performed real-time PCR experiments 
to examine gene expression levels of 14 genes (GDNF, PTPN12, ADAM22, FZD1, TFPI2, 
GNG11, COL1A2, SMURF1, VGF, RELN, GPAA1, PLEC, SHARPIN) in 12 primary 
melanoma cell lines (WM35, HT199, WM1789, WM793B, WM3211, WM1361, WM902B, 
WM39, WM278, WM983A, WM1366, WM3248).  
Good correlation was found between copy number and gene expression data. Invasive cell 
lines showed remarkably decreased relative PTPN12, ADAM22, FZD1, SMURF1, VGF and 
RELN expression levels, and increased GLIPR1 mRNA expression compared to non-invasive 
cell lines, with significant difference for the FZD1 and SMURF1 genes (P=0.028 and 
P=0.028). Furthermore, the mRNA levels of PTPN1, ADAM22, FZD1 and SMURF1 were 
significantly correlated with aCGH results (log2 ratio). Detailed descriptions and illustrations 
are presented below: 
 
Page 7, line 6: additional section included into the “Methods”  
 
Real time quantitative PCR analysis 
The relative expression level of the selected genes was determined by quantitative real-time 
PCR in 12 primary melanoma cell lines (WM35, HT199, WM1789, WM793B, WM3211, 
WM1361, WM902B, WM39, WM278, WM983A, WM1366 and WM3248) using  LightCycler® 
480 Real-Time PCR System (Roche Diagnostics, GmbH, Mannheim, Germany). Reverse 
transcription was carried out on total RNA (600 ng) using the High Capacity cDNA Archive 
Kit (Applied Biosystems, Carlsbad, California, USA). To perform qPCR reactions SYBR 
premix Ex taq (Takara, Japan) master mix was used. Primer sequences of 14 candidate genes 
are listed in Supplementary Table 1.  
PCR data were analyzed using the Livak method (2−ΔΔCt), with glyceraldehyde-3-phosphate 
dehydrogenase (Hs99999905_m1) as the reference gene and the median Ct value of 8 non-
invasive cell lines as the control value (calibrator sample)[3].  
 
Additional “Supplementary Table 1” 
 
Supplementary Table 1 - Primer sequences used in RT-qPCR experiments 
Gene Primer sequence (5’-3’)1 Amplicon size (bp)2 
GNDF F: GAAGCAGCAGTTACCAGACA 87 
 R: GGAGCAGAAAGGACAGAGAAG  
PTPN12 F: GGTGCTGTGACCCAGAATAA 70 
 R: CAGTACTAGTGGCAGCAGAAA  
ADAM22 F: GTGTCTTCCTGTGGCTTCTT 69 
 R: CCTGAGCAAATAGTGCCTTCT  
FZD1 F: AAGACCGAGTGGTGTGTAATG 100 
 R: AGCATCATGAAGAGGATGGTG  
TFPI2 F: GTCAGGGACTGGTTGAAGATT 100 
 R: CTAGGCCCTGTGTTTCTTATGT  
GNG11 F: GTGCTACTCATCTTTGCTCACTA 60 
 R: ACATCTGATACTCTCTGCTCTCT  
COL1A2 F: AGAGTGGAGCAGTGGTTACTA 100 
 R: GATACAGGTTTCGCCAGTAGAG  
SMURF1 F: GGAGTCTTACCGCCAGATAATG 96 
 R: CCACCGTAATCCAAACCTTCT  
VGF F: TGTGTGAAGTGTGTCTGTCTC 74 
 R: ATTCACAGCGACTTGGAGAG  
RELN F: TCATGGCACCCATTGGTAAG 75 
 R: CAGGATCCGTTGCAGATGATAG  
GPAA1 F: TGGGCCAAAGATATCGTCTTC 88 
 R: TGACATTGACATCGTGGTAGG  
PLEC F: GGCACTGCGTAGGAAATACA 100 
 R: CTCGTTCAGCTGTTCCTTCTC  
SHARPIN F: CCTTCCTGCACCTTCATCAAT 61 
 R: TCTGGGTGCTACACATCTCA  
GAPDH F: AGCCACATCGCTCAGACAC 66 
 R: GCCCAATACGACCAAATCC  
1F: forward, R: reverse; 2bp: base pair 
 
 
Page 8, line 7: Additional sentence included into the “Statistical analysis” of “Methods” 
section:  
 
Mann-Whitney-Wilcoxon test was used to compare the mRNA expression of non-invasive cell 
lines to invasive ones. 
 
 
Page 10, line 8: Additional section inserted into the “Results” section:  
 
Relative mRNA expression of candidate genes 
To determine the influence of CN alterations on the gene expression, we examined the relative 
mRNA level of the 14 candidate genes using real time PCR method (Table 3). Seven of these 
genes (GLIPR1, PTPN12, ADAM22, FZD1, SMURF1, VGF and RELN) were either up- or 
down-regulated in the same manner as it was expected from of gene copy numbers based on 
aCGH data (Figure 4A). Relative mRNA expression of FZD1 and SMURF1 genes were 
significantly lower in invasive cell lines compared to non-invasive ones. By correlating the 
relative expression levels (log2 transformed) with aCGH results (log2 ratios), we identified 4 
genes (PTPN12, ADAM22, FZD1 and SMURF1) that mRNA level was significantly 
correlated with copy number changes (Figure 4B).  
 
New figure included as Figure 4: 
 
  
Figure 4. Analysis of relative expression levels by real time quantitative PCR 
(A) Comparison of the relative mRNA expressions of the non-invasive (WM35, WM1798, 
WM793B, WM1361, WM902B, WM39, WM278, WM3248) and invasive cell lines (HT199, 
WM983A, WM1366, WM3211). The data are presented as mean ± S.D of non-invasive (N=8) 
and invasive (N=4) cell lines (3 replicates per sample). *Expression was significantly higher 
in non-invasive cell lines than in the invasive cells (p0.05). (B) Correlation analysis between 
log2 transformed expression levels and aCGH results (log2 ratios). Pearson’s correlation 
coefficients (R) are shown in the graphs (p0.05). 
 
Modified parts of the “Discussion” section: 
 
Page 12, line 2: 
According to the mRNA expression analyses, downregulation of PTPN12, ADAM22, FZD1, 
SMURF1, VGF and RELN genes was characteristic of the invasive cell lines compared to 
non-invasive ones. Although alterations of these genes have already been reported in a 
variety of invasive tumours; we provide the first evidence that the structural and functional 
alterations of these genes have fundamental role in melanoma invasion.  
 
Page 12, line 11: 
The mRNA expression level of GLIPR1 gene was notably higher in invasive cell lines than in 
non-invasive lines, confirming that upregulation of the gene is associated with increased 
invasive potential in melanoma. 
 
 
 
 
 
REVIEWER 2 
 
First we would like to thank the Reviewer for thoroughly reviewing our manuscript. For the 
suggestion of the Reviewer we performed new additional analyses as well as experiments. In 
our response we have labeled the Reviewer questions with bold italic. The new text in our 
response appears as underlined italic.  
 
Identifying genes, genetic mutations and pathways linked to the development of an invasive 
melanoma phenotype continues to be a challenging task. The approach used in this study 
was to study the genetic alteration of chromosomes and chromosomal regions 
characteristic of primary melanoma cell lines demonstrating an invasive phenotype in a 
functional matrigel based assay of cell invasion. Array comparative genomic hybridization 
(aCGH) was then used to examine common chromosomal gain and loss alterations within 
these grouped cell lines. While I have reservations in the use of the matrigel invasion 
chamber assay to ascribe invasive potential, as these are notoriously variable and time 
dependent on a day to day basis, the findings are consistent with the chromosomal gains 
seen in cell lines derived from metastatic tumour tissue, and thereby by definition with 
metastatic potential. 
 
Minor corrections: 
There is much made in the Introduction on the genetic alterations seen in melanoma 
including BRAF, NRAS, RAC1 etc. It may be appropriate to cite the very recent landmark 
publication on the 4 genomic classifications of melanomas.  
Viz. 
Genomic Classification of Cutaneous Melanoma.  
Cancer Genome Atlas Network.  
Cell. 2015 Jun 18;161(7):1681-96 
 
In agreement with the Reviewer’s suggestion we cited the publication mentioned above (page 
3, line 22). 
 
 
2.) In addition to the comment above the BRAF/NRAS/RAC1 and other appropriate gene 
mutations as known in the cell lines could be incorporated into a separate column of Table 
1.  
 
The requested data were incorporated into a separate column of Table 1. In case of 12 cell 
lines (WM35, WM1789, WM793B, WM3211, WM1361, WM39, WM278, WM983A, 
WM1366, WM3248, WM1617, WM983B) the BRAF and NRAS mutation status were 
previously characterized and provided by the American Type Culture Collection (Manassas, 
VA, USA) and the Coriell Institute for Medical Research (Camden, NJ, USA). If the 
mutational status of these genes were not available we determined it using real-time PCR.  
 
See the completed Table 1 below, under the response of the 3rd comment.  
 
Page 6, line 7: Additional section in “Methods”  
 
Detection of BRAF and NRAS mutations  
The BRAF and NRAS mutation status of the melanoma cell lines (A2058, HT168, M24, M24 
MET, HT199, and WM902B) was determined by RT-PCR. All the other cell lines were 
previously tested for these mutations (data provided by the ATCC or Coriell Institute). The 
mutations in codon 600 of BRAF and codon 61 of NRAS were analysed on a LightCycler real-
time PCR System (Roche Diagnostics GmbH, Mannheim, Germany) by melting curve analysis 
using fluorescent probes. Primers and probes were purchased from TIB Molbiol (Berlin, 
Germany) and the reaction was performed as described previously [4]. The mutation status of 
the analysed cell lines are shown in Table 1. 
 
 
3.) In the methods section p6 it is stated that the "data are presented as the means +/- SD of 
three independent experiments". This data is missing from Table 1 or is there meant to be a 
Supplementary Table? On p7, what is the definition for "4 of the 12 cell lines displayed 
invasive property (Figure 2)". 
 
In agreement with the suggestion of the Reviewer we completed Table 1 with the data of the 
invasive property of every cell lines (revised Table 1.)  
We considered a cell line as non-invasive if there were no invaded cells in the three 
independent experiment using Matrigel invasion assay. The Matrigel Matrix serves as a 
reconstituted basement membrane in vitro. The layer occludes the pores of the membrane, 
blocking non-invasive cells from migrating through the membrane. In contrast, invasive cells 
(malignant and non-malignant) are able to detach themselves from and invade through the 
Matrigel Matrix and the 8 micron membrane pores. [5-8]. On page 7 in order to make it clear 
we modified the sentence as follows: “According to the Matrigel invasion assays, we 
observed invasive cells in four out of the twelve cell lines originated from primary melanoma 
tissues.” 
 
 
Revised Table 1: 
 
Table 1 Characteristics of human melanoma cell lines 
Cell line Origina 
Growth 
Phaseb 
Histologic 
Typec 
BRAF 
mutation 
statusd 
NRAS 
mutation 
statuse 
Invaded 
cell/field 
(mean ± SD)f 
WM35 primary RGP SSM V600E wt 0.0 ± 0.0 
HT199 primary RGP NM V600E wt 15.0 ± 3.3 
WM1789 primary RGP/VGP SSM K601E wt 0.0 ± 0.0 
WM793B primary RGP/VGP SSM V600E wt 0.0 ± 0.0 
WM3211 primary RGP/VGP SSM wt wt 76.5 ± 29.5 
WM1361 primary VGP SSM wt Q61L 0.0 ± 0.0 
WM902B primary VGP SSM V600E wt 0.0 ± 0.0 
WM39 primary VGP NM V600E wt 0.0 ± 0.0 
WM278p1 primary VGP NM V600E wt 0.0 ± 0.0 
WM983Ap2 primary VGP n.d. V600E wt 4.7 ± 2.0 
WM1366 primary VGP n.d. wt Q61L 13.0 ± 1.4 
WM3248 primary VGP n.d. V600E wt 0.0 ± 0.0 
WM1617m1 metastasis - - V600E wt 0.0 ± 0.0 
WM983Bm2 metastasis - - V600E wt 3.3 ± 2.4 
A2058 metastasis - - V600E wt 30.0 ± 3.6 
HT168 metastasis - - V600E wt 26.7 ± 5.2 
M24 metastasis - - wt Q61R 27.0 ± 4.9 
M24 MET metastasis - - wt Q61R 74.0 ± 5.4 
atumor type of melanomas which the cell lines were derived from; bRGP: radial growth phase, 
VGP: vertical growth phase; cSSM: superficial spreading melanoma, NM: nodular melanoma, 
n.d.: no data; dV: valine, E: glutamic acid, K: lysine, wt: wild-type; eQ: glutamine, L: leucine, 
R: arginine; fdata are presented as the mean ± SD of three independent invasion assay 
experiments; pprimary tumor derived cell line with metastatic pair from the same patient; 
mmetastatic pair of primary derived cell line 
 
 
4.) Under the heading "Validation of array CGH data" p8, Figure 3B should be cited 
somewhere. 
 
In agreement with this comment we cited Figure 3 in the “Validation of array CGH data”. 
However, we cited Figure 3A instead of 3B, since the copy number validation was performed 
in case of 3 genes (COL1A2, RELN and GLIPR1) which are represented on the column chart 
in Figure 3A.  
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Abstract 
 
Malignant melanoma is one of the most aggressive human cancers. Invasion of cells is 
the first step in metastasis, resulting in cell migration through tissue compartments.  
We aimed to evaluate genomic alterations specifically associated with the invasive 
characteristics of melanoma cells. Matrigel invasion assays were used to determine the 
invasive properties of cell lines originated from primary melanomas. Array comparative 
genomic hybridisation (aCGH) analyses were performed to define the chromosome 
copy number alterations (CNAs).  Several recurrent CNAs were identified by aCGH 
that affected melanoma-related genes. Invasive primary cell lines displayed high 
frequencies of CNAs, including the loss of 7q and gain of 12q chromosomal regions 
targeting PTPN12, ADAM22, FZD1, TFPI2, GNG11, COL1A2, SMURF1, VGF, RELN 
and GLIPR1 genes.. Gain of the GDNF (5p13.1), GPAA1, PLEC and SHARPIN 
(8q24.3) genes were significantly more frequent in invasive cell lines compared to the 
non-invasive ones. Importantly, copy number gains of these genes were also found in 
cell lines originated from metastases, suggesting their role in melanoma metastasis 
formation.   
The present study describes genomic differences between invasive and non-invasive 
melanoma cell lines that may contribute to the aggressive phenotype of human 
melanoma cells.  
 
Keywords: invasion, malignant melanoma, copy number alteration, array aCGH 
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Introduction  
 
Malignant melanoma is considered one of the most aggressive human cancers because 
of its high metastatic propensity [1-5]. Cutaneous melanoma develops from 
melanocytes, which originate from highly motile neural crest progenitors that migrate 
through the skin during embryonic development [6, 7]. Efficacy of current therapies is 
not a question of tumour stage, but is dependent on the individual genetic alterations, 
mutational status and rapid progression of melanoma tumour [8].  
Metastasis formation of primary tumours is a multi-step process that includes tumour 
cell invasion, intravasation to vessels, survival in the circulatory system, extravasation 
and proliferation, leading to metastatic colonisation [9-11]. The acquisition of invasive 
potential is one of the key transition in the progression of benign tumours to life-
threatening metastatic melanoma [12]. In order to efficiently metastasise, invasive 
melanoma cells change their cytoskeletal organisation and alter their contacts with the 
extracellular matrix (ECM) and the surrounding stroma [2]. Apart from the collective 
invasive strategy, where cells invade as multicellular units by forming strands or sheets, 
individual tumour cells can also migrate through tissue compartments separated by the 
basement membrane [2, 10, 11]. Furthermore, the invasive strategy of melanoma cells 
depends on the microenvironment and the effects of therapeutic regimens [13-16].  
Numerous genetic alterations (e.g., BRAF, NRAS, RAC1 mutations) and deregulated 
signalling pathways (e.g., altered activity of Rho GTPases, MAPK and PI3K molecules) 
have been shown to be associated with invasive behaviour [2, 12, 17-20]. Despite these 
essential therapeutic targets, an effective overall therapy is still missing [21, 22]. 
Although our knowledge of melanoma cell motility has increased in the last decades, 
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the complexity of the diverse invasive strategies requires further research [9, 13, 14, 
23]. 
In an effort to further advance the understanding of the relationship between copy 
number (CN) alterations and the invasiveness of melanoma, we performed array aCGH 
analyses on 18 primary melanoma cell lines. This study has important implications for 
understanding the complexity of melanoma development and progression. 
 
Methods 
 
Cell culture 
Melanoma cell lines (WM35, HT199, A2058, HT168, M24, M24 MET) were obtained 
from the American Type Culture Collection (Manassas, VA, USA) and the other cell 
lines (WM1789, WM793B, WM3211, WM1361, WM902B, WM39, WM278, 
WM983A, WM1366, WM3248, WM1617, WM983B) were from the Coriell Institute 
for Medical Research (Camden, NJ, USA). The clinicopathological characteristics of 
the cell lines are summarised in Table 1. The cells were cultured in RPMI 1640 medium 
(Lonza Group Ltd., Basel, Switzerland) or MCDB153-L15 medium (Sigma-Aldrich Co. 
LCC, MO, USA) supplemented with 5-10% foetal bovine serum (Gibco, CA, USA) at 
37 °C in an atmosphere containing 5% CO2. Genomic DNA was isolated using the G-
spin Genomic DNA extraction kit (Intron Biotechnology, Inc., Korea) according to the 
manufacturer’s protocol. The concentration and quality of the DNA were determined 
using a NanoDrop ND-1000 UV-Vis Spectrophotometer. The ratio of the absorbance at 
260 nm and 280 nm was used to determine the purity of the DNA (a ratio ≥1.8 was 
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accepted as high quality). The integrity of the DNA was verified by standard 1.2% 
agarose gel electrophoresis. 
 
Array aCGH and data analysis 
DNA samples were hybridised to Cytochip ISCA 8X60 arrays (BlueGnome Ltd., UK) 
with increased probe density in regions or genes associated with known constitutional 
disorders. Array data were analysed using BlueFuse Multi v2.2 software (BlueGnome 
Ltd., UK) and Nexus Copy Number 6.1 software (BioDiscovery Inc., CA, USA). To 
adjust the sensitivity of the segmentation algorithm, we determined a significance 
threshold of 1.0E-6 and specified 1000 kb as the maximum spacing between adjacent 
probes. To eliminate small CNAs, the minimum number of probes per segment was set 
at 5. To detect gains and losses, the following log2 ratio thresholds were set: ±0.3 for 
gains and losses, 0.6 for high CN gains and -1.0 for homozygous deletions. 
Significantly different CN events between invasive versus non-invasive melanoma cell 
lines were identified by applying two-sided Fisher’s exact test. The FDR adjustment 
was calculated to correct for multiple testing using the Nexus Copy Number 6.1 
Comparison feature. To avoid sex bias, all probes on chromosomes X and Y were 
discarded. 
 
In vitro invasion assay 
The invasive potential of the melanoma cell lines was analysed using BD Biocoat 
Matrigel invasion chambers (pore size: 8 μm, 24-well; BD Biosciences, Bedford, MA, 
USA). The upper chamber of the insert was filled with 500 µl of cell suspension in 
serum-free media (5x104 cells/well). Medium containing 10% FBS was applied to the 
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lower chamber as a chemoattractant. After the cells were incubated for 24 h at 37 °C, 
cells in the lower layer were fixed with methanol and stained with hematoxylin-eosin. 
The invaded cells were counted using a light microscope in 7 different visual fields at 
200X magnification, and the data are presented as the means±SD of three independent 
experiments.  
 
Detection of BRAF and NRAS mutations 
The BRAF and NRAS mutation status of the melanoma cell lines A2058, HT168, M24, 
M24 MET, HT199, and WM902B was determined. All the other cell lines were 
previously tested for these mutations (data provided by the ATCC or Coriell Institute). 
The mutations in codon 600 of BRAF and codon 61 of NRAS were analysed on a 
LightCycler real-time PCR System (Roche Diagnostics GmbH, Mannheim, Germany) 
by melting curve analysis using fluorescent probes. Primers and probes were purchased 
from TIB Molbiol (Berlin, Germany) and the reaction was performed as described 
previously [24]. The mutation status of the analysed cell lines is shown in Table 1. 
 
 
TaqMan Copy Number Assay 
Real time quantitative PCR (qPCR) method was used on 18 melanoma cell lines to 
confirm the aCGH results. Copy numbers of GLIPR1, COL1A2 and RELN genes were 
assessed using pre-designed TaqMan® Copy Number Assays as described previously 
[25]. Predesigned TaqMan® Copy Number Assays were used to analyse copy numbers 
(Hs01421756_cn, Hs03071873_cn and Hs02363915_cn, respectively), and the RNase P 
gene was applied as a reference gene (Applied Biosystems Inc., USA). All assays were 
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performed with TaqMan® Universal PCR Master Mix according to the manufacturer's 
protocol (Applied Biosystems Inc., USA). Samples with RNase P Ct value over 32 were 
excluded from further analysis. CopyCaller® Software v.2.0 was used to calculate copy 
numbers.  
 
Real time quantitative PCR analysis 
The relative expression level of the selected genes was determined by quantitative real-
time PCR in 12 primary melanoma cell lines (WM35, HT199, WM1789, WM793B, 
WM3211, WM1361, WM902B, WM39, WM278, WM983A, WM1366 and WM3248) 
using  LightCycler® 480 Real-Time PCR System (Roche Diagnostics, GmbH, 
Mannheim, Germany). Reverse transcription was carried out on total RNA (600 ng) 
using the High Capacity cDNA Archive Kit (Applied Biosystems, Carlsbad, California, 
USA). To perform qPCR reactions SYBR premix Ex taq (Takara, Japan) master mix 
was used. Primer sequences of 14 candidate genes are listed in Supplementary Table 1.  
PCR data were analyzed using the Livak method (2−ΔΔCt), with glyceraldehyde-3-
phosphate dehydrogenase (Hs99999905_m1) as the reference gene and the median Ct 
value of 8 non-invasive cell lines as the control value (calibrator sample) [26]. 
 
The Cancer Genome Atlas (TCGA) data analysis 
aCGH data of melanoma samples deposited into the Skin Cutaneous Melanoma dataset 
(TCGA, Provisional) were analyzed. The results shown are in whole based upon data 
generated by the TCGA Research Network (http://cancergenome.nih.gov). Dataset 
includes GISTIC-CNA data of 366 melanoma samples. Data mining was performed 
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using cBioPortal (http://www.cbioportal.org/) [27, 28]. All searches were done 
according to the cBioPortal's instructions. 
 
Statistical analysis 
SPSS 19.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. The 
Shapiro–Wilk test was used to evaluate the normality of the data. Pearson’s correlation 
coefficient was calculated to correlate the aCGH and qPCR data. Mann-Whitney-
Wilcoxon test was used to compare the mRNA expression of non-invasive cell lines to 
invasive ones. P < 0.05 was considered statistically significant. 
 
Results 
 
aCGH analysis 
Detailed genomic analyses using the CytoChip ISCA array were performed to evaluate 
the CN alterations in 18 human melanoma cell lines that originated from primary (n=12) 
and metastatic (n=6) tumours. A high degree of CN instability was identified across the 
genomes of all cell lines, involving CN gains in 1q, 6p, 7, 8q, 17q, 20 and 22q and CN 
losses in 6q, 9p and 10p. We observed CN alterations of several melanoma-related 
genes (Figure 1).  
 
Recurrent regions related to invasiveness  
To identify genomic alterations that are uniquely related to the invasive potential of 
melanomas, in vitro invasion assays were performed on cell lines derived from primary 
malignant melanomas (WM35, HT199, WM1789, WM793B, WM3211, WM1361, 
9 
 
WM902B, WM39, WM278, WM983A, WM1366 and WM3248) in order to determine 
the invasive potential of each cell line. According to the Matrigel invasion assays, 4 of 
the 12 cell lines displayed invasive property. According to the Matrigel invasion assays, 
we observed invasive cells in four out of the twelve cell lines originated from primary 
melanoma tissues (Figure 2).  
Several CN alterations occurred at significantly higher frequencies in cell lines showing 
invasive behaviour compared with the non-invasive lines (Table 2). Although a number 
of these altered regions mapped to known regions of germline CNV, we did not exclude 
these from further analyses since well-validated cancer relevant genes have been known 
to locate in regions of germline CNV [29, 30]. 
We identified copy number changes on 7q and 12q that appeared specifically in cell 
lines with invasive behaviour (Figure 3.A). The targeted genes within these regions 
included the loss of several invasion-related genes (PTPN12, ADAM22, FZD1, TFPI2, 
GNG11, COL1A2, SMURF1, VGF, RELN and GLIPR1). Additionally, the gain of 5p13 
and 8q24 were present not solely in invasive cell lines but occurred in metastasis-
derived cell lines as well, harbouring GDNF (5p13.1), GPAA1, PLEC and SHARPIN 
(8q24.3) as invasion-related genes.  
 
Copy number alterations of candidate genes in melanoma tumor samples  
The Skin Cutaneous Melanoma dataset (TCGA, Provisional) gives the opportunity to 
determine the relevance of the alterations associated with invasive melanoma cell lines 
in native melanoma tissues. As most of the melanoma samples are metastatic and there 
is no available data regarding the invasive capacity of the primary tumors in the TCGA 
database, we focused on the genes (GDNF, GPAA1, PLEC, SHARPIN) which copy 
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number alterations were detected not uniquely in invasive but also in metastasis-derived 
cell lines, assuming the role of these genes in both invasion and metastasis formation.. 
These genes were not altered by copy number changes in the primary lesion. 
Interestingly, GPAA1, PLEC and SHARPIN were co-amplified in 26 metastatic samples, 
whereas GDNF was found to be amplified only in 14 metastatic tissues.   
 
Relative mRNA expression of candidate genes 
To determine the influence of CN alterations on the gene expression, we examined the 
relative mRNA level of the 14 candidate genes using real time PCR method (Table 3). 
Seven of these genes (GLIPR1, PTPN12, ADAM22, FZD1, SMURF1, VGF and RELN) 
were either up- or down-regulated in the same manner as it was expected from of gene 
copy numbers based on aCGH data (Figure 4A). Relative mRNA expression of FZD1 
and SMURF1 genes were significantly lower in invasive cell lines compared to non-
invasive ones. By correlating the relative expression levels (log2 transformed) with 
aCGH results (log2 ratios), we identified 4 genes (PTPN12, ADAM22, FZD1 and 
SMURF1) that mRNA level was significantly correlated with copy number changes 
(Figure 4B). 
 
Validation of array aCGH data  
Real time quantitative PCR method was performed using TaqMan® Copy Number 
Assays to detect copy numbers of COL1A2, RELN and GLIPR1 genes. Pearson’s 
correlations were then calculated between the aCGH data using the mean log2 ratios of 
probes covering the aforementioned genes (Figure 3A) and the normalized copy 
numbers determined by qPCR method. Good concordance was found between the data 
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derived from the array aCGH and qPCR methods. The correlation coefficients revealed 
moderate and strong correlation between our datasets; 0.659, 0.695 and 0.555, 
respectively (p=0.003, p=0.001, p=0.017).  
 
 
Discussion 
 
Cytogenetic heterogeneity resulting from chromosomal instability is a major driving 
force of melanoma progression. Invasion is one of the first steps of metastasis formation 
in primary tumours; however, insufficient data are available on the genetic alterations 
involved in this initial process in melanoma. In this study, we used whole genome array 
aCGH profiling to detect chromosomal alterations in a set of melanoma cell lines.  
According to our aCGH results, the overall pattern of genomic alterations was in close 
agreement with previously published data [30-34]. Gains of whole chromosomes or 
chromosome arms were observed across the 1q, 6p, 7, 8q, 17q, 20 and 22q regions, 
whereas losses were frequently found in chromosomes 6q, 9p and 10p. CN changes of 
several well-known oncogenes (EGFR, NEDD9, MYC and BRAF) and tumorsuppressor 
genes (CDKN2A, CDKN2B) related to melanoma progression were detected [35-39]. 
Our main goal was to identify the invasive potential of multiple melanoma cell lines 
derived from primary melanomas and compared the CN changes between the invasive 
and non-invasive subgroups. We report several CN alterations that were uniquely 
detected in invasive cell lines. Loss of 7q appeared to associate with invasive behaviour; 
targeting genes whose deletion or down-regulation can potentially increase melanoma 
cell invasion (e.g., PTPN12, ADAM22, FZD1, TFPI2, GNG11, COL1A2, SMURF1, 
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VGF and RELN). According to the mRNA expression analyses of this study, 
downregulation of PTPN12, ADAM22, FZD1, SMURF1, VGF and RELN genes was 
characteristic of the invasive cell lines compared to non-invasive ones. Although 
alterations in these genes have already been reported in a variety of invasive tumours; 
we provide the first evidence for the fundamental role of these gene alterations in 
melanoma invasion that the structural and functional alterations of these genes have 
fundamental role in melanoma invasion. [40-47].  
According to previous studies, after the translocation of the GLIPR1 (GLI pathogenesis-
related 1) protein to the cell surface, the soluble N-terminal domain of the molecule is 
exposed to the extracellular space, which can lead to invasion [48, 49]. In the present 
study, gain of the GLIPR1 gene was observed specifically in invasive cell lines 
confirming that elevated levels of GLIPR1 are associated with increased invasive 
potential in melanoma. The mRNA expression level of GLIPR1 gene was notably 
higher in invasive cell lines than in non-invasive lines confirming that upregulation of 
the gene is associated with increased invasive potential in melanoma [48]. 
We also aimed to identify CN alterations that are appeared in the metastatic-derived cell 
lines besides the invasive primary lines. We found that the gain of GDNF (5p13.1), 
GPAA1, PLEC and SHARPIN (8q24.3) genes was detected collectively in invasive and 
metastatic cell lines, indicating the possible roles for role of these genes in both invasive 
process invasion and metastasis formation. In addition, these genes showed copy 
number alterations in metastatic melanoma tissues of the TCGA (Provisional) 
melanoma dataset, supporting the relevance of these genes during the progression, 
metastasis formation of melanoma cells. Results of previous studies have shown that 
upregulated GDNF (glial cell derived neurotrophic factor) can induce proliferation and 
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invasion of melanoma cells through activating the MAPK and PI3K pathways [50, 51]. 
The overexpression of GPAA1 (glycosylphosphatidylinositol anchor attachment 1) 
could induce tumour invasion as well [52, 53]. Plectin (PLEC) is a multifunctional 
plakin protein that is essential for the integrity of skin, skeletal and cardiac muscle; it 
can regulate actin assembly and cell migration [54]. In addition, a recent study 
demonstrated the role of overexpressed SHARPIN (SHANK-associated RH domain 
interactor) in the activation of NFκB pathway and its downstream targets affecting cell 
invasion and metastasis [55]. The function of GPAA1, PLEC and SHARPIN in 
association with melanoma invasion and metastasis formation has not been mentioned 
previously.  
In summary, our systematic comparison of CN alterations between cell lines with 
different invasive properties revealed several remarkable genomic alterations in 
invasive melanoma cells. CN changes of various invasion-related genes were observed 
for the first time in invasive melanoma cell lines. Furthermore, our data highlight the 
possible role for the gain of GDNF, GPAA1, PLEC and SHARPIN genes in metastasis 
formation as well. Our genomic analysis of human melanoma cell lines and the 
classification of CN alterations associated with melanoma invasiveness thus provide 
novel candidate genes for further functional studies.  
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Figure legends 
 
Figure 1. Summary of array aCGH results obtained from 18 melanoma cell lines 
(A) Individual chromosomal profiles of melanoma cell lines. Red indicates CN (copy 
number) losses, and blue represents CN gains. (B) The most frequently altered 
chromosomal regions in 18 melanoma cell lines with melanoma related genes. 
 
Figure 2. Invasive potential of primary tumour-derived cell lines  
Cells were cultured in Matrigel invasion chambers for 24 h. Following incubation, the 
invaded cells were fixed and stained with hematoxylin-eosin (A). The data are presented 
as the mean±S.D. of three independent experiments (B).  
 
Figure 3. Characterisation of invasive primary melanoma cell lines by array 
aCGH 
(A) CN (copy number) changes uniquely observed in invasive primary cell lines 
(HT199, WM983A, WM1366, WM3211) in contrast with non-invasive primary- 
(WM35, WM1798, WM793B, WM1361, WM902B, WM39, WM278, WM3248) and 
metastatic-tumour derived cells (A2058, HT168, M24, M24 MET, WM1617, 
WM983B) targeting invasion associated genes.  (B) CN changes detected in both 
invasive primary tumour-derived and metastatic-tumour derived cell lines targeting 
invasion related candidate genes. 
 
Figure 4. Analysis of relative expression levels by real time quantitative PCR 
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(A) Comparison of the relative mRNA expressions of the non-invasive (WM35, 
WM1798, WM793B, WM1361, WM902B, WM39, WM278, WM3248) and invasive 
cell lines (HT199, WM983A, WM1366, WM3211). The data are presented as mean ± 
S.D of non-invasive (N=8) and invasive (N=4) cell lines (3 replicates per sample). 
*Expression was significantly higher in non-invasive cell lines than in the invasive cells 
(p0.05). (B) Correlation analysis between log2 transformed expression levels and 
aCGH results (log2 ratios). Pearson’s correlation coefficients (R) are shown in the 
graphs (p0.05). 
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Abstract 
 
Malignant melanoma is one of the most aggressive human cancers. Invasion of cells is 
the first step in metastasis, resulting in cell migration through tissue compartments.  
We aimed to evaluate genomic alterations specifically associated with the invasive 
characteristics of melanoma cells. Matrigel invasion assays were used to determine the 
invasive properties of cell lines originated from primary melanomas. Array comparative 
genomic hybridisation (aCGH) analyses were performed to define the chromosome 
copy number alterations (CNAs).  Several recurrent CNAs were identified by aCGH 
that affected melanoma-related genes. Invasive primary cell lines displayed high 
frequencies of CNAs, including the loss of 7q and gain of 12q chromosomal regions 
targeting PTPN12, ADAM22, FZD1, TFPI2, GNG11, COL1A2, SMURF1, VGF, RELN 
and GLIPR1 genes.. Gain of the GDNF (5p13.1), GPAA1, PLEC and SHARPIN 
(8q24.3) genes were significantly more frequent in invasive cell lines compared to the 
non-invasive ones. Importantly, copy number gains of these genes were also found in 
cell lines originated from metastases, suggesting their role in melanoma metastasis 
formation.   
The present study describes genomic differences between invasive and non-invasive 
melanoma cell lines that may contribute to the aggressive phenotype of human 
melanoma cells.  
 
Keywords: invasion, malignant melanoma, copy number alteration, aCGH 
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Introduction  
 
Malignant melanoma is considered one of the most aggressive human cancers because 
of its high metastatic propensity [1-5]. Cutaneous melanoma develops from 
melanocytes, which originate from highly motile neural crest progenitors that migrate 
through the skin during embryonic development [6, 7]. Efficacy of current therapies is 
not a question of tumour stage, but is dependent on the individual genetic alterations, 
mutational status and rapid progression of melanoma tumour [8].  
Metastasis formation of primary tumours is a multi-step process that includes tumour 
cell invasion, intravasation to vessels, survival in the circulatory system, extravasation 
and proliferation, leading to metastatic colonisation [9-11]. The acquisition of invasive 
potential is one of the key transition in the progression of benign tumours to life-
threatening metastatic melanoma [12]. In order to efficiently metastasise, invasive 
melanoma cells change their cytoskeletal organisation and alter their contacts with the 
extracellular matrix (ECM) and the surrounding stroma [2]. Apart from the collective 
invasive strategy, where cells invade as multicellular units by forming strands or sheets, 
individual tumour cells can also migrate through tissue compartments separated by the 
basement membrane [2, 10, 11]. Furthermore, the invasive strategy of melanoma cells 
depends on the microenvironment and the effects of therapeutic regimens [13-16].  
Numerous genetic alterations (e.g., BRAF, NRAS, RAC1 mutations) and deregulated 
signalling pathways (e.g., altered activity of Rho GTPases, MAPK and PI3K molecules) 
have been shown to be associated with invasive behaviour [2, 12, 17-20]. Despite these 
essential therapeutic targets, an effective overall therapy is still missing [21, 22]. 
Although our knowledge of melanoma cell motility has increased in the last decades, 
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the complexity of the diverse invasive strategies requires further research [9, 13, 14, 
23]. 
In an effort to further advance the understanding of the relationship between copy 
number (CN) alterations and the invasiveness of melanoma, we performed aCGH 
analyses on 18 melanoma cell lines. This study has important implications for 
understanding the complexity of melanoma development and progression. 
 
Methods 
 
Cell culture 
Melanoma cell lines (WM35, HT199, A2058, HT168, M24, M24 MET) were obtained 
from the American Type Culture Collection (Manassas, VA, USA) and the other cell 
lines (WM1789, WM793B, WM3211, WM1361, WM902B, WM39, WM278, 
WM983A, WM1366, WM3248, WM1617, WM983B) were from the Coriell Institute 
for Medical Research (Camden, NJ, USA). The clinicopathological characteristics of 
the cell lines are summarised in Table 1. The cells were cultured in RPMI 1640 medium 
(Lonza Group Ltd., Basel, Switzerland) or MCDB153-L15 medium (Sigma-Aldrich Co. 
LCC, MO, USA) supplemented with 5-10% foetal bovine serum (Gibco, CA, USA) at 
37 °C in an atmosphere containing 5% CO2. Genomic DNA was isolated using the G-
spin Genomic DNA extraction kit (Intron Biotechnology, Inc., Korea) according to the 
manufacturer’s protocol. The concentration and quality of the DNA were determined 
using a NanoDrop ND-1000 UV-Vis Spectrophotometer. The ratio of the absorbance at 
260 nm and 280 nm was used to determine the purity of the DNA (a ratio ≥1.8 was 
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accepted as high quality). The integrity of the DNA was verified by standard 1.2% 
agarose gel electrophoresis. 
 
aCGH and data analysis 
DNA samples were hybridised to Cytochip ISCA 8X60 arrays (BlueGnome Ltd., UK) 
with increased probe density in regions or genes associated with known constitutional 
disorders. Array data were analysed using BlueFuse Multi v2.2 software (BlueGnome 
Ltd., UK) and Nexus Copy Number 6.1 software (BioDiscovery Inc., CA, USA). To 
adjust the sensitivity of the segmentation algorithm, we determined a significance 
threshold of 1.0E-6 and specified 1000 kb as the maximum spacing between adjacent 
probes. To eliminate small CNAs, the minimum number of probes per segment was set 
at 5. To detect gains and losses, the following log2 ratio thresholds were set: ±0.3 for 
gains and losses, 0.6 for high CN gains and -1.0 for homozygous deletions. 
Significantly different CN events between invasive versus non-invasive melanoma cell 
lines were identified by applying two-sided Fisher’s exact test. The FDR adjustment 
was calculated to correct for multiple testing using the Nexus Copy Number 6.1 
Comparison feature. To avoid sex bias, all probes on chromosomes X and Y were 
discarded. 
 
In vitro invasion assay 
The invasive potential of the melanoma cell lines was analysed using BD Biocoat 
Matrigel invasion chambers (pore size: 8 μm, 24-well; BD Biosciences, Bedford, MA, 
USA). The upper chamber of the insert was filled with 500 µl of cell suspension in 
serum-free media (5x104 cells/well). Medium containing 10% FBS was applied to the 
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lower chamber as a chemoattractant. After the cells were incubated for 24 h at 37 °C, 
cells in the lower layer were fixed with methanol and stained with hematoxylin-eosin. 
The invaded cells were counted using a light microscope in 7 different visual fields at 
200X magnification, and the data are presented as the means±SD of three independent 
experiments.  
 
Detection of BRAF and NRAS mutations 
The BRAF and NRAS mutation status of the melanoma cell lines A2058, HT168, M24, 
M24 MET, HT199, and WM902B was determined. All the other cell lines were 
previously tested for these mutations (data provided by the ATCC or Coriell Institute). 
The mutations in codon 600 of BRAF and codon 61 of NRAS were analysed on a 
LightCycler real-time PCR System (Roche Diagnostics GmbH, Mannheim, Germany) 
by melting curve analysis using fluorescent probes. Primers and probes were purchased 
from TIB Molbiol (Berlin, Germany) and the reaction was performed as described 
previously [24]. The mutation status of the analysed cell lines is shown in Table 1. 
 
 
TaqMan Copy Number Assay 
Real time quantitative PCR (qPCR) method was used on 18 melanoma cell lines to 
confirm the aCGH results. Copy numbers of GLIPR1, COL1A2 and RELN genes were 
assessed using pre-designed TaqMan® Copy Number Assays as described previously 
[25]. Predesigned TaqMan® Copy Number Assays were used to analyse copy numbers 
(Hs01421756_cn, Hs03071873_cn and Hs02363915_cn, respectively), and the RNase P 
gene was applied as a reference gene (Applied Biosystems Inc., USA). All assays were 
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performed with TaqMan® Universal PCR Master Mix according to the manufacturer's 
protocol (Applied Biosystems Inc., USA). Samples with RNase P Ct value over 32 were 
excluded from further analysis. CopyCaller® Software v.2.0 was used to calculate copy 
numbers.  
 
Real time quantitative PCR analysis 
The relative expression level of the selected genes was determined by quantitative real-
time PCR in 12 primary melanoma cell lines (WM35, HT199, WM1789, WM793B, 
WM3211, WM1361, WM902B, WM39, WM278, WM983A, WM1366 and WM3248) 
using  LightCycler® 480 Real-Time PCR System (Roche Diagnostics, GmbH, 
Mannheim, Germany). Reverse transcription was carried out on total RNA (600 ng) 
using the High Capacity cDNA Archive Kit (Applied Biosystems, Carlsbad, California, 
USA). To perform qPCR reactions SYBR premix Ex taq (Takara, Japan) master mix 
was used. Primer sequences of 14 candidate genes are listed in Supplementary Table 1.  
PCR data were analyzed using the Livak method (2−ΔΔCt), with glyceraldehyde-3-
phosphate dehydrogenase (Hs99999905_m1) as the reference gene and the median Ct 
value of 8 non-invasive cell lines as the control value (calibrator sample) [26]. 
 
The Cancer Genome Atlas (TCGA) data analysis 
aCGH data of melanoma samples deposited into the Skin Cutaneous Melanoma dataset 
(TCGA, Provisional) were analyzed. The results shown are in whole based upon data 
generated by the TCGA Research Network (http://cancergenome.nih.gov). Dataset 
includes GISTIC-CNA data of 366 melanoma samples. Data mining was performed 
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using cBioPortal (http://www.cbioportal.org/) [27, 28]. All searches were done 
according to the cBioPortal's instructions. 
 
Statistical analysis 
SPSS 19.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. The 
Shapiro–Wilk test was used to evaluate the normality of the data. Pearson’s correlation 
coefficient was calculated to correlate the aCGH and qPCR data. Mann-Whitney-
Wilcoxon test was used to compare the mRNA expression of non-invasive cell lines to 
invasive ones. P < 0.05 was considered statistically significant. 
 
Results 
 
aCGH analysis 
Detailed genomic analyses using the CytoChip ISCA array were performed to evaluate 
the CN alterations in 18 human melanoma cell lines that originated from primary (n=12) 
and metastatic (n=6) tumours. A high degree of CN instability was identified across the 
genomes of all cell lines, involving CN gains in 1q, 6p, 7, 8q, 17q, 20 and 22q and CN 
losses in 6q, 9p and 10p. We observed CN alterations of several melanoma-related 
genes (Figure 1).  
 
Recurrent regions related to invasiveness  
To identify genomic alterations that are uniquely related to the invasive potential of 
melanomas, in vitro invasion assays were performed on cell lines derived from primary 
malignant melanomas (WM35, HT199, WM1789, WM793B, WM3211, WM1361, 
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WM902B, WM39, WM278, WM983A, WM1366 and WM3248) in order to determine 
the invasive potential of each cell line. According to the Matrigel invasion assays, we 
observed invasive cells in four out of the twelve cell lines originated from primary 
melanoma tissues (Figure 2).  
Several CN alterations occurred at significantly higher frequencies in cell lines showing 
invasive behaviour compared with the non-invasive lines (Table 2). Although a number 
of these altered regions mapped to known regions of germline CNV, we did not exclude 
these from further analyses since well-validated cancer relevant genes have been known 
to locate in regions of germline CNV [29, 30]. 
We identified copy number changes on 7q and 12q that appeared specifically in cell 
lines with invasive behaviour (Figure 3.A). The targeted genes within these regions 
included the loss of several invasion-related genes (PTPN12, ADAM22, FZD1, TFPI2, 
GNG11, COL1A2, SMURF1, VGF, RELN and GLIPR1). Additionally, the gain of 5p13 
and 8q24 were present not solely in invasive cell lines but occurred in metastasis-
derived cell lines as well, harbouring GDNF (5p13.1), GPAA1, PLEC and SHARPIN 
(8q24.3) as invasion-related genes.  
 
Copy number alterations of candidate genes in melanoma tumor samples  
The Skin Cutaneous Melanoma dataset (TCGA, Provisional) gives the opportunity to 
determine the relevance of the alterations associated with invasive melanoma cell lines 
in native melanoma tissues. As most of the melanoma samples are metastatic and there 
is no available data regarding the invasive capacity of the primary tumors in the TCGA 
database, we focused on the genes (GDNF, GPAA1, PLEC, SHARPIN) which copy 
number alterations were detected not uniquely in invasive but also in metastasis-derived 
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cell lines, assuming the role of these genes in both invasion and metastasis formation.. 
These genes were not altered by copy number changes in the primary lesion. 
Interestingly, GPAA1, PLEC and SHARPIN were co-amplified in 26 metastatic samples, 
whereas GDNF was found to be amplified only in 14 metastatic tissues.   
 
Relative mRNA expression of candidate genes 
To determine the influence of CN alterations on the gene expression, we examined the 
relative mRNA level of the 14 candidate genes using real time PCR method (Table 3). 
Seven of these genes (GLIPR1, PTPN12, ADAM22, FZD1, SMURF1, VGF and RELN) 
were either up- or down-regulated in the same manner as it was expected from of gene 
copy numbers based on aCGH data (Figure 4A). Relative mRNA expression of FZD1 
and SMURF1 genes were significantly lower in invasive cell lines compared to non-
invasive ones. By correlating the relative expression levels (log2 transformed) with 
aCGH results (log2 ratios), we identified 4 genes (PTPN12, ADAM22, FZD1 and 
SMURF1) that mRNA level was significantly correlated with copy number changes 
(Figure 4B). 
 
Validation of aCGH data  
Real time quantitative PCR method was performed using TaqMan® Copy Number 
Assays to detect copy numbers of COL1A2, RELN and GLIPR1 genes. Pearson’s 
correlations were then calculated between the aCGH data using the mean log2 ratios of 
probes covering the aforementioned genes (Figure 3A) and the normalized copy 
numbers determined by qPCR method. Good concordance was found between the data 
derived from the aCGH and qPCR methods. The correlation coefficients revealed 
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moderate and strong correlation between our datasets; 0.659, 0.695 and 0.555, 
respectively (p=0.003, p=0.001, p=0.017).  
 
 
Discussion 
 
Cytogenetic heterogeneity resulting from chromosomal instability is a major driving 
force of melanoma progression. Invasion is one of the first steps of metastasis formation 
in primary tumours; however, insufficient data are available on the genetic alterations 
involved in this initial process in melanoma. In this study, we used whole genome 
aCGH profiling to detect chromosomal alterations in a set of melanoma cell lines.  
According to our aCGH results, the overall pattern of genomic alterations was in close 
agreement with previously published data [30-34]. Gains of whole chromosomes or 
chromosome arms were observed across the 1q, 6p, 7, 8q, 17q, 20 and 22q regions, 
whereas losses were frequently found in chromosomes 6q, 9p and 10p. CN changes of 
several well-known oncogenes (EGFR, NEDD9, MYC and BRAF) and tumorsuppressor 
genes (CDKN2A, CDKN2B) related to melanoma progression were detected [35-39]. 
Our main goal was to identify the invasive potential of multiple melanoma cell lines 
derived from primary melanomas and compared the CN changes between the invasive 
and non-invasive subgroups. We report several CN alterations that were uniquely 
detected in invasive cell lines. Loss of 7q appeared to associate with invasive behaviour; 
targeting genes whose deletion or down-regulation can potentially increase melanoma 
cell invasion (e.g., PTPN12, ADAM22, FZD1, TFPI2, GNG11, COL1A2, SMURF1, 
VGF and RELN). According to the mRNA expression analyses of this study, 
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downregulation of PTPN12, ADAM22, FZD1, SMURF1, VGF and RELN genes was 
characteristic of the invasive cell lines compared to non-invasive ones. Although 
alterations in these genes have already been reported in a variety of invasive tumours; 
we provide the first evidence that the structural and functional alterations of these genes 
have fundamental role in melanoma invasion. [40-47].  
According to previous studies, after the translocation of the GLIPR1 (GLI pathogenesis-
related 1) protein to the cell surface, the soluble N-terminal domain of the molecule is 
exposed to the extracellular space, which can lead to invasion [48, 49]. In the present 
study, gain of the GLIPR1 gene was observed specifically in invasive cell lines. The 
mRNA expression level of GLIPR1 gene was notably higher in invasive cell lines than 
in non-invasive lines confirming that upregulation of the gene is associated with 
increased invasive potential in melanoma [48]. 
We also aimed to identify CN alterations that are appeared in the metastatic-derived cell 
lines besides the invasive primary lines. We found that the gain of GDNF (5p13.1), 
GPAA1, PLEC and SHARPIN (8q24.3) genes was detected in invasive and metastatic 
cell lines, indicating the possible role of these genes in both invasion and metastasis 
formation. In addition, these genes showed copy number alterations in metastatic 
melanoma tissues of the TCGA (Provisional) melanoma dataset, supporting the 
relevance of these genes during the progression, metastasis formation of melanoma 
cells. Results of previous studies have shown that upregulated GDNF (glial cell derived 
neurotrophic factor) can induce proliferation and invasion of melanoma cells through 
activating the MAPK and PI3K pathways [50, 51]. The overexpression of GPAA1 
(glycosylphosphatidylinositol anchor attachment 1) could induce tumour invasion as 
well [52, 53]. Plectin (PLEC) is a multifunctional plakin protein that is essential for the 
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integrity of skin, skeletal and cardiac muscle; it can regulate actin assembly and cell 
migration [54]. In addition, a recent study demonstrated the role of overexpressed 
SHARPIN (SHANK-associated RH domain interactor) in the activation of NFκB 
pathway and its downstream targets affecting cell invasion and metastasis [55]. The 
function of GPAA1, PLEC and SHARPIN in association with melanoma invasion and 
metastasis formation has not been mentioned previously.  
In summary, our systematic comparison of CN alterations between cell lines with 
different invasive properties revealed several remarkable genomic alterations in 
invasive melanoma cells. CN changes of various invasion-related genes were observed 
for the first time in invasive melanoma cell lines. Furthermore, our data highlight the 
possible role for the gain of GDNF, GPAA1, PLEC and SHARPIN genes in metastasis 
formation as well. Our genomic analysis of human melanoma cell lines and the 
classification of CN alterations associated with melanoma invasiveness thus provide 
novel candidate genes for further functional studies.  
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Figure legends 
 
Figure 1. Summary of aCGH results obtained from 18 melanoma cell lines 
(A) Individual chromosomal profiles of melanoma cell lines. Red indicates CN (copy 
number) losses, and blue represents CN gains. (B) The most frequently altered 
chromosomal regions in 18 melanoma cell lines with melanoma related genes. 
 
Figure 2. Invasive potential of primary tumour-derived cell lines  
Cells were cultured in Matrigel invasion chambers for 24 h. Following incubation, the 
invaded cells were fixed and stained with hematoxylin-eosin (A). The data are presented 
as the mean±S.D. of three independent experiments (B).  
 
Figure 3. Characterisation of invasive primary melanoma cell lines by aCGH 
(A) CN (copy number) changes uniquely observed in invasive primary cell lines 
(HT199, WM983A, WM1366, WM3211) in contrast with non-invasive primary- 
(WM35, WM1798, WM793B, WM1361, WM902B, WM39, WM278, WM3248) and 
metastatic-tumour derived cells (A2058, HT168, M24, M24 MET, WM1617, 
WM983B) targeting invasion associated genes.  (B) CN changes detected in both 
invasive primary tumour-derived and metastatic-tumour derived cell lines targeting 
invasion related candidate genes. 
 
Figure 4. Analysis of relative expression levels by real time quantitative PCR 
(A) Comparison of the relative mRNA expressions of the non-invasive (WM35, 
WM1798, WM793B, WM1361, WM902B, WM39, WM278, WM3248) and invasive 
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cell lines (HT199, WM983A, WM1366, WM3211). The data are presented as mean ± 
S.D of non-invasive (N=8) and invasive (N=4) cell lines (3 replicates per sample). 
*Expression was significantly higher in non-invasive cell lines than in the invasive cells 
(p0.05). (B) Correlation analysis between log2 transformed expression levels and 
aCGH results (log2 ratios). Pearson’s correlation coefficients (R) are shown in the 
graphs (p0.05). 
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Table 1 Characteristics of human melanoma cell lines 
Cell line Origina 
Growth 
Phaseb 
Histologic 
Typec 
BRAF 
mutation 
statusd 
NRAS 
mutation 
statuse 
Invaded 
cell/field 
(mean ± SD)f 
WM35 primary RGP SSM V600E wt 0.0 ± 0.0 
HT199 primary RGP NM V600E wt 15.0 ± 3.3 
WM1789 primary RGP/VGP SSM K601E wt 0.0 ± 0.0 
WM793B primary RGP/VGP SSM V600E wt 0.0 ± 0.0 
WM3211 primary RGP/VGP SSM wt wt 76.5 ± 29.5 
WM1361 primary VGP SSM wt Q61L 0.0 ± 0.0 
WM902B primary VGP SSM V600E wt 0.0 ± 0.0 
WM39 primary VGP NM V600E wt 0.0 ± 0.0 
WM278p1 primary VGP NM V600E wt 0.0 ± 0.0 
WM983Ap2 primary VGP n.d. V600E wt 4.7 ± 2.0 
WM1366 primary VGP n.d. wt Q61L 13.0 ± 1.4 
WM3248 primary VGP n.d. V600E wt 0.0 ± 0.0 
WM1617m1 metastasis - - V600E wt 0.0 ± 0.0 
WM983Bm2 metastasis - - V600E wt 3.3 ± 2.4 
A2058 metastasis - - V600E wt 30.0 ± 3.6 
HT168 metastasis - - V600E wt 26.7 ± 5.2 
M24 metastasis - - wt Q61R 27.0 ± 4.9 
M24 MET metastasis - - wt Q61R 74.0 ± 5.4 
atumor type of melanomas which the cell lines were derived from; bRGP: radial growth phase, VGP: 
vertical growth phase; cSSM: superficial spreading melanoma, NM: nodular melanoma, n.d.: no data; 
dV: valine, E: glutamic acid, K: lysine, wt: wild-type; eQ: glutamine, L: leucine, R: arginine; fdata are 
Table
presented as the mean ± SD of three independent invasion assay experiments; pprimary tumor 
derived cell line with metastatic pair from the same patient; mmetastatic pair of primary derived cell 
line 
Table 2 Chromosomal regions occurring with significantly higher frequencies in the invasive cell lines 
Cytoband location 
Region 
Length (bp) 
Event 
No. of 
genes 
Frequency in 
non-invasive 
cell lines (%) 
Frequency in 
invasive cell 
lines (%) 
P-
Valuea 
Candidate genes 
4q22.1 - q22.2 1,063,318 CN Loss 2 0.0 75.0 0.018 n.c. 
4q31.3 723,382 CN Loss 2 0.0 75.0 0.018 n.c. 
4q35.1 722,510 CN Loss 4 0.0 75.0 0.018 n.c. 
5p13.2 1,427,307 CN Gain 8 0.0 75.0 0.018  GDNF 
7q11.23 59,511 CN Loss 2 0.0 75.0 0.018 n.c. 
7q11.23 - q21.11 2,663,721 CN Loss 15 0.0 75.0 0.018 PTPN12 
7q21.11 - q21.3 13,825,784 CN Loss 69 0.0 75.0 0.018 ADAM22, FZD1, TFPI2, 
GNG11, COL1A2 
7q21.3 - q22.1 7,948,023 CN Loss 157 0.0 75.0 0.018 SMURF1, VGF, RELN 
8q24.3 1,233,778 CN Gain 51 0.0 75.0 0.018  GPAA1, PLEC, SHARPIN 
aP-Value was determined by a multiple corrected Fisher’s exact test; CN: copy number;  n.c.: no candidate gene. 
Supplementary Table 1 - Primer sequences used in RT-qPCR experiments 
Gene Primer sequence (5’-3’)1 Amplicon size (bp)2 
GNDF F: GAAGCAGCAGTTACCAGACA 87 
 R: GGAGCAGAAAGGACAGAGAAG  
PTPN12 F: GGTGCTGTGACCCAGAATAA 70 
 R: CAGTACTAGTGGCAGCAGAAA  
ADAM22 F: GTGTCTTCCTGTGGCTTCTT 69 
 R: CCTGAGCAAATAGTGCCTTCT  
FZD1 F: AAGACCGAGTGGTGTGTAATG 100 
 R: AGCATCATGAAGAGGATGGTG  
TFPI2 F: GTCAGGGACTGGTTGAAGATT 100 
 R: CTAGGCCCTGTGTTTCTTATGT  
GNG11 F: GTGCTACTCATCTTTGCTCACTA 60 
 R: ACATCTGATACTCTCTGCTCTCT  
COL1A2 F: AGAGTGGAGCAGTGGTTACTA 100 
 R: GATACAGGTTTCGCCAGTAGAG  
SMURF1 F: GGAGTCTTACCGCCAGATAATG 96 
 R: CCACCGTAATCCAAACCTTCT  
VGF F: TGTGTGAAGTGTGTCTGTCTC 74 
 R: ATTCACAGCGACTTGGAGAG  
RELN F: TCATGGCACCCATTGGTAAG 75 
 R: CAGGATCCGTTGCAGATGATAG  
GPAA1 F: TGGGCCAAAGATATCGTCTTC 88 
 R: TGACATTGACATCGTGGTAGG  
PLEC F: GGCACTGCGTAGGAAATACA 100 
Supplementary Table
 R: CTCGTTCAGCTGTTCCTTCTC  
SHARPIN F: CCTTCCTGCACCTTCATCAAT 61 
 R: TCTGGGTGCTACACATCTCA  
GAPDH F: AGCCACATCGCTCAGACAC 66 
 R: GCCCAATACGACCAAATCC  
1F: forward, R: reverse; 2bp: base pair 
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